A thrombin receptor function for platelet glycoprotein Ib–IX unmasked by cleavage of glycoprotein V
- Vanitha Ramakrishnan*,†,
- Francis DeGuzman*,
- Ming Bao*,
- Scott W. Hall‡,
- Lawrence L. Leung‡, and
- David R. Phillips*
- *COR Therapeutics, Inc., South San Francisco, CA 94080; and ‡Division of Hematology, Stanford University School of Medicine, Palo Alto, CA 94305
-
Edited by Philip W. Majerus, Washington University School of Medicine, St. Louis, MO, and approved November 29, 2000 (received for review October 26, 2000)
Abstract
Glycoprotein (GP) V is a major substrate cleaved by the protease thrombin during thrombin-induced platelet activation. Previous analysis of platelets from GP V-null mice suggested a role for GP V as a negative modulator of platelet activation by thrombin. We now report the mechanism by which thrombin activates GP V −/− platelets. We show that proteolytically inactive forms of thrombin induce robust stimulatory responses in GP V null mouse platelets, via the platelet GP Ib–IX–V complex. Because proteolytically inactive thrombin can activate wild-type mouse and human platelets after treatment with thrombin to cleave GP V, this mechanism is involved in thrombin-induced platelet aggregation. Platelet activation through GP Ib–IX depends on ADP secretion, and specific inhibitors demonstrate that the recently cloned P2Y12 ADP receptor (Gi-coupled ADP receptor) is involved in this pathway, and that the P2Y1 receptor (Gq-coupled ADP receptor) may play a less significant role. Thrombosis was generated in GP V null mice only in response to catalytically inactive thrombin, whereas thrombosis occurred in both genotypes (wild type and GP V null) in response to active thrombin. These data support a thrombin receptor function for the platelet membrane GP Ib–IX–V complex, and describe a novel thrombin signaling mechanism involving an initiating proteolytic event followed by stimulation of the GP Ib–IX via thrombin acting as a ligand, resulting in platelet activation.
Footnotes
-
↵ † To whom reprint requests should be addressed at: COR Therapeutics, Inc., 256 East Grand Avenue, South San Francisco, CA 94080. E-mail: vramakrishnan{at}corr.com.
-
This paper was submitted directly (Track II) to the PNAS office.
-
See commentary on page 1330.
- Abbreviations:
- GP,
- glycoprotein;
- GP V f1,
- cleaved GP V;
- vWf,
- von Willebrand factor;
- PAR,
- protease-activated receptor;
- CHO,
- Chinese hamster ovary;
- DIP-,
- diisopropylphospho-;
- DFP,
- diisopropyl fluorophosphate;
- WP,
- washed platelets;
- wt,
- wild type;
- PGI2,
- prostacyclin;
- PGE1,
- prostaglandin E1
- Copyright © 2001, The National Academy of Sciences








